Expression and purification of recombinant human receptor for advanced glycation endproducts in Escherichia coli.
The receptor for advanced glycation endproducts (RAGE) is a multiligand receptor that binds a variety of structurally and functionally unrelated ligands, including advanced glycation endproducts (AGEs), amyloid fibrils, amphoterin, and members of the S100 family of proteins. The receptor has been implicated in the pathology of diabetes as well as in inflammatory processes and tumor cell metastasis. For the present study, the extracellular region of RAGE (exRAGE) was expressed as a soluble, C-terminal hexahistidine-tagged fusion protein in the periplasmic space of Escherichia coli. Proper processing and folding of the purified protein, predicted to contain three immunoglobulin-type domains, was supported by the results of electrospray mass spectroscopy and circular dichroism experiments. Sedimentation velocity experiments showed that exRAGE was primarily monomeric in solution. Binding to several RAGE ligands, including AGE-BSA, immunoglobulin light chain amyloid fibrils, and glycosaminoglycans, was demonstrated using pull-down, dot-blot, or enzyme-linked microplate assays. Using surface plasmon resonance, the interaction of exRAGE with AGE-BSA was shown to fit a two-site model, with KD values of 88 nM and 1.4 microM. The E. coli-derived exRAGE did not bind the advanced glycation endproduct Nepsilon-(carboxymethyl)lysine, as reported for the cellular receptor, and the possible role of RAGE glycosylation in recognition of this ligand is discussed. This new RAGE construct will facilitate detailed studies of RAGE-ligand interactions and provides a platform for preparation of site-directed mutants for future structure/function studies.
Wilton
Rosemarie
R
Biosciences Division, Argonne National Laboratory, Argonne, IL 60439, and Department of Biochemistry and Molecular Biology and Biophysics Core Facility, University of Chicago 60637, USA. rwilton@anl.gov
Yousef
Mohammed A
MA
Saxena
Poonam
P
Szpunar
Mercedes
M
Stevens
Fred J
FJ
D000682:Amyloid / Q000235:genetics / Q000378:metabolism; D000686:Amyloidosis / Q000378:metabolism; D003001:Cloning, Molecular; D004926:Escherichia coli / Q000235:genetics* / Q000378:metabolism; D005110:Extracellular Space / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D017127:Glycation End Products, Advanced / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007135:Immunoglobulin Variable Region / Q000235:genetics; D008024:Ligands; D008956:Models, Chemical; D016297:Mutagenesis, Site-Directed; D010446:Peptide Fragments / Q000096:biosynthesis / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D011485:Protein Binding / Q000235:genetics; D017434:Protein Structure, Tertiary / Q000235:genetics; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000096:biosynthesis / Q000235:genetics* / Q000302:isolation & purification*
D000682:Amyloid; D017127:Glycation End Products, Advanced; D007135:Immunoglobulin Variable Region; D008024:Ligands; D010446:Peptide Fragments; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic; C035222:amyloid protein AL